General Biologicals Corporation (TPEX:4117)
Taiwan · Delayed Price · Currency is TWD 10.20
-0.10 (-0.97%)
Aug 19, 2026, 1:20 PM CST
General Biologicals Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 260.23 | 215.74 | 251.93 | 264.83 | 370.46 | 551.66 | |
Revenue Growth | 3.52% | -14.36% | -4.87% | -28.51% | -32.85% | 15.93% |
Cost of Revenue | 168.1 | 156.12 | 244.39 | 202.12 | 198.61 | 269.72 |
Gross Profit | 92.14 | 59.62 | 7.54 | 62.71 | 171.85 | 281.94 |
Selling, General & Admin | 196.44 | 207.46 | 171.15 | 200.27 | 180.58 | 219.64 |
Research & Development | 64.92 | 64.55 | 49.53 | 36.25 | 35.85 | 34.25 |
Other Operating Expenses | -31.91 | -16.09 | - | - | - | - |
Operating Expenses | 231.8 | 256.66 | 223.32 | 232.64 | 212.72 | 238.14 |
Operating Income | -139.67 | -197.05 | -215.78 | -169.94 | -40.87 | 43.79 |
Interest Expense | -47.42 | -41.79 | -13.37 | -11.98 | -16.86 | -11 |
Interest & Investment Income | 1.82 | 2 | 2.34 | 2.66 | 1.08 | 0.49 |
Earnings From Equity Investments | -6.53 | 0.01 | -0.25 | -6.93 | -1.34 | -0.16 |
Currency Exchange Gain (Loss) | -3.64 | -3.64 | 2.11 | -0.84 | 7.34 | -0.87 |
Other Non Operating Income (Expenses) | 12.61 | 0.74 | -0.22 | -5.58 | 4.38 | 2.41 |
EBT Excluding Unusual Items | -182.83 | -239.74 | -225.17 | -192.61 | -46.27 | 34.66 |
Gain (Loss) on Sale of Investments | -2.91 | -2.91 | 3.05 | 4.89 | 0.44 | -5.82 |
Gain (Loss) on Sale of Assets | 748.16 | 748.16 | - | - | -0.38 | 9.77 |
Other Unusual Items | - | - | - | - | 0.09 | - |
Pretax Income | 562.41 | 505.51 | -222.11 | -187.72 | -46.13 | 38.61 |
Income Tax Expense | 44.24 | 40.67 | -0.29 | 12.13 | 7.69 | -5.48 |
Earnings From Continuing Operations | 518.17 | 464.84 | -221.82 | -199.85 | -53.82 | 44.08 |
Minority Interest in Earnings | 0.81 | 1.01 | 1 | 1.01 | 0.63 | 0.06 |
Net Income | 518.98 | 465.84 | -220.82 | -198.83 | -53.19 | 44.14 |
Net Income to Common | 518.98 | 465.84 | -220.82 | -198.83 | -53.19 | 44.14 |
Net Income Growth | - | - | - | - | - | -28.98% |
Shares Outstanding (Basic) | 68 | 62 | 60 | 60 | 60 | 60 |
Shares Outstanding (Diluted) | 68 | 63 | 60 | 60 | 60 | 60 |
Shares Change | 13.03% | 4.62% | - | - | -0.14% | 13.44% |
EPS (Basic) | 7.68 | 7.46 | -3.69 | -3.32 | -0.89 | 0.74 |
EPS (Diluted) | 7.67 | 7.44 | -3.69 | -3.32 | -0.89 | 0.74 |
EPS Growth | - | - | - | - | - | -37.38% |
Free Cash Flow | -87.01 | -307.28 | -1,735 | -198.33 | -23.42 | 24.24 |
Free Cash Flow Per Share | -1.29 | -4.91 | -29.00 | -3.31 | -0.39 | 0.41 |
Gross Margin | 35.41% | 27.63% | 2.99% | 23.68% | 46.39% | 51.11% |
Operating Margin | -53.67% | -91.34% | -85.65% | -64.17% | -11.03% | 7.94% |
Profit Margin | 199.43% | 215.93% | -87.65% | -75.08% | -14.36% | 8.00% |
Free Cash Flow Margin | -33.44% | -142.43% | -688.57% | -74.89% | -6.32% | 4.40% |
EBITDA | -56.45 | -131.23 | -195.25 | -150.37 | -22.69 | 64.95 |
EBITDA Margin | -21.69% | -60.83% | -77.50% | -56.78% | -6.12% | 11.77% |
D&A For EBITDA | 83.21 | 65.82 | 20.54 | 19.57 | 18.19 | 21.16 |
EBIT | -139.67 | -197.05 | -215.78 | -169.94 | -40.87 | 43.79 |
EBIT Margin | -53.67% | -91.34% | -85.65% | -64.17% | -11.03% | 7.94% |
Effective Tax Rate | 7.87% | 8.05% | - | - | - | - |